FDA Adverse Events Reports (FAERS) Summary for VIBRAMYCIN

These tables and charts are based on 1,249 total reports for VIBRAMYCIN (DOXYCYCLINE) received by the FDA Adverse Event Reporting System (FAERS) from 2004 through April 28, 2026.

This FAERS total includes 1,205 pharmaceutical company-submitted and non-U.S. FAERS reports and 44 U.S. consumer or healthcare provider-submitted MedWatch reports. For a separate summary of the 44 U.S. reports filed via the FDA MedWatch voluntary reporting system, view our FDA MedWatch VIBRAMYCIN summary report. (See notes section below for explanation of FDA’s mandatory and voluntary reporting system.)

Top 20 Adverse Effects Associated with VIBRAMYCIN (reported in FAERS Database)

	Side Effect	# of FDA Reports
1	DRUG HYPERSENSITIVITY	135
2	DIARRHEA	91
3	SHORTNESS OF BREATH	85
4	FATIGUE	80
5	NAUSEA	77
6	FEVER	69
7	PAIN	67
8	RASH	66
9	OFF LABEL USE	51
10	ACUTE KIDNEY INJURY	50
11	PNEUMONIA	50
12	VOMITING	50
13	LACK OF STRENGTH AND ENERGY (ASTHENIA)	48
14	ANXIETY	47
15	HEADACHE	46
16	CHRONIC KIDNEY DISEASE	45
17	DIZZINESS	45
18	DECREASED APPETITE	42
19	DRUG INEFFECTIVE	42
20	HIGH BLOOD PRESSURE	41
21	WEIGHT DECREASED	41
22	COUGH	36
23	SINUSITIS	36
24	ABDOMINAL PAIN	34
25	DEPRESSION	33
26	KIDNEY FAILURE	33
27	MALAISE	32
28	JOINT PAIN	31
29	URINARY TRACT INFECTION	31
30	ANEMIA	30
31	DEHYDRATION	30
32	PAIN IN EXTREMITY	30
33	PINS AND NEEDLES	29
34	DEATH	28
35	BREATHLESSNESS	28
36	METALLIC OR ALTERED TASTE	27
37	HIVES	27
38	BACK PAIN	25
39	NUMBNESS	25
40	INSOMNIA	25
41	KIDNEY PAIN	24
42	CONSTIPATION	23
43	EJECTION FRACTION DECREASED	23
44	FALL	23
45	MUSCLE PAIN	23
46	CONFUSIONAL STATE	22
47	DRUG INTERACTION	22
48	DIFFICULTY SWALLOWING	22
49	SKIN REDNESS	22
50	GASTROOESOPHAGEAL REFLUX DISEASE	22
51	LOW BLOOD PRESSURE	22
52	ITCHING	22
53	INFECTION	21
54	FLANK PAIN	20
55	GAIT DISTURBANCE	20
56	SWELLING OF LIMBS	20
57	EMOTIONAL DISTRESS	19
58	MUSCLE SPASMS	19
59	NEUROPATHY PERIPHERAL	19
60	ABDOMINAL PAIN UPPER	18
61	CELLULITIS	18
62	CHRONIC OBSTRUCTIVE PULMONARY DISEASE	18
63	CONDITION AGGRAVATED	18
64	INJURY	18
65	POLYNEUROPATHY	18
66	TREMOR	18
67	WEIGHT INCREASED	18
68	ACUTE RESPIRATORY FAILURE	17
69	ATRIAL FIBRILLATION	17
70	KIDNEY FAILURE	17
71	HAEMOGLOBIN DECREASED	17
72	THROMBOCYTOPENIA	17
73	ABDOMINAL DISCOMFORT	16
74	ABDOMINAL DISTENSION	16
75	DISEASE PROGRESSION	16
76	EXCESS SWEATING	16
77	PLEURAL EFFUSION	16
78	DROWSINESS	16
79	RAPID HEART RATE (TACHYCARDIA)	16
80	CONGESTIVE HEART FAILURE	15
81	PULMONARY EMBOLISM	15
82	BLOOD PRESSURE INCREASED	14
83	BRONCHITIS	14
84	CHEST DISCOMFORT	14
85	CHEST PAIN	14
86	CHILLS	14
87	FEELING ABNORMAL	14
88	HYPERSENSITIVITY	14
89	MUSCULAR WEAKNESS	14
90	SEPSIS	14
91	FAINTING	14
92	WHITE BLOOD CELL COUNT INCREASED	14
93	ASPARTATE AMINOTRANSFERASE INCREASED	13
94	GASTROINTESTINAL BLEEDING	13
95	HYPOXIA	13
96	ILL-DEFINED DISORDER	13
97	JOINT SWELLING	13
98	STEVENS-JOHNSON SYNDROME	13
99	TOXICITY TO VARIOUS AGENTS	13
100	WHITE BLOOD CELL COUNT DECREASED	13

Latest Known Outcomes for Reactions Reported for VIBRAMYCIN

	Latest Known Outcome for Reported Reactions	Number of Cases
1	Unknown Outcome	634
2	Patient recovered	279
3	Patient has not recovered/symtoms have not resolved	248
4	Patient is recovering/symptoms resolving	138
5	Patient died	62
6	Patient has recovered but has consequent health issues	9

Search all MedWatch and FAERS by keyword:

VIBRAMYCIN Total Reports

Male	Female	Unknown	Total
420	715	114	1,249

Top Countries Reporting

	Country	Number of Reports
1	United States	718
2	Japan	98
3	Austria	38
4	Greece	22
5	Switzerland	20
6	Canada	12
7	United Kingdom	12
8	Germany	5
9	Australia	4
10	Egypt	4

Outcomes for Reports

Serious: 899
Not Serious: 350
Note: A serious outcome means the adverse event resulted in death, a life threatening condition, hospitalization, disability, congenital anomaly, or other serious condition.

Top Indications

Top Companies Reporting

PFIZER
PFIZER

Safety-Related FDA Updates

VIBRAMYCIN (DOXYCYCLINE) Rx Drug:
Barbiturates, carbamazepine, phenytoin, and rifampin shorten the half-life of doxycycline, thereby lowering doxycycline concentration in the body. Safety-related Labeling Changes

Have experience (good or bad) with VIBRAMYCIN? Rate VIBRAMYCIN at Ask a Patient.

For serious adverse events, report them to the FDA by contacting the drug manufacturer or report directly through the MedWatch voluntary reporting form.

Notes

This report, created by AskaPatient.com, is derived from the cases for VIBRAMYCIN reported to the United States Food and Drug Administration (FDA) FDA Safety Information and Adverse Event Reporting System (FAERS) and obtained from Open FDA. Data was last updated with reports received through April 28, 2026.

This summary includes ALL reports where the drug is a "primary OR secondary OR suspected interacting" drug. Typically, reports are filed for the most serious type or "event" and do not represent incidental or minor side effects. The majority of these reports are mandatory reports submitted by pharmaceutical companies, who receive complaints from consumers. The reactions, side effects, or "adverse events," represent up to the 20 most frequently occuring events in the database for a drug related to the event. This report also features counts of latest known outcomes associated with reported side effects, but does not provide the specific outcomes for specific adverse events.

Adverse Event Reports are submitted to the FAERS database by pharmaceutical companies (mandatory reporting is required by manufacturers, distributors, or importers). Health care providers such as doctors (voluntary reporting), and patients themselves (voluntary reporting) report to the FDA directly through the MedWatch program. Those MedWatch reports are coded and included in the FAERS database. This report mainly consists of the mandatory reports, because the MedWatch reports are a small percentage (3 - 5%) of total reports. Link to the MedWatch summary report at the top of the page for a summary of the directly reported (voluntary) adverse events for this drug.The number of reports included here might differ somewhat from the number of reports in the downloadable quarterly FAERS reports and in the online FAERS dashboard, due to lags in reporting, drug name differences, duplicates, and other factors. Open FDA states that it only includes the most recent version of a case report. It also adds the disclaimer: "Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated."

FDA uses the "MedDRA" classification system to describe reported adverse reactions. MedDRA is a standardized medical terminology that facilitates sharing of regulatory information internationally. In some cases, "patient friendly" terms for the layman designated by MedDRA have been substituted for medical jargon. Please contact us with questions or comments about this report.